Eagle Biologics, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Arsia Therapeutics, Inc. (to 2017)
0
Ending by 2030
Sep 2034
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due May 21, 2027The maintenance fee for Liquid Protein Formulations Containing Cyclic Adenosine Monophosphate (cAMP) or Adenosine Triphosphate (ATP) (US 11,819,550) comes due May 21, 2027. Unpaid by Nov 22, 2027, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Liquid Protein Formulations Containing Cimetidine (US 10,646,571) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,646,571 | Liquid Protein Formulations Containing Cimetidine In force · Medium confidence | In force | Medium confidence | |
| US 10,821,184 | Liquid Protein Formulations Containing Thiamine Pyrophosphate (TPP) In force · High confidence | In force | High confidence | |
| US 10,849,977 | Liquid Protein Formulations Containing Thiamine In force · Low confidence | In force | Low confidence | |
| US 10,821,183 | Liquid Protein Formulations Containing 4-(3-butyl-1-imidazolio)-1-butane sulfonate (BIM) In force · Medium confidence | In force | Medium confidence | |
| US 11,819,550 | Liquid Protein Formulations Containing Cyclic Adenosine Monophosphate (cAMP) or Adenosine Triphosphate (ATP) In force · Medium confidence | In force | Medium confidence | |
| US 10,179,172 | Liquid Pharmaceutical Formulations for Injection Comprising Yellow 5 or Orange G and Uses Thereof In force · High confidence | In force | High confidence | |
| US 11,986,526 | Liquid Protein Formulations Containing 4-Ethyl-4-Methylmorpholinium Methylcarbonate (EMMC) In force · Medium confidence | In force | Medium confidence | |
| US 9,833,513 | Liquid Protein Formulations for Injection Comprising 1-Butyl-3-Methylimidazolium Methanesulfonate and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,913,905 | Liquid Pharmaceutical Formulations for Injection Comprising Thiamine Pyrophosphate 1-(3-Aminopropyl)-2-Methyl-1H-IMIDAZOLE and Uses Thereof In force · High confidence | In force | High confidence | |
| US 9,925,263 | Liquid Pharmaceutical Formulations for Injection Comprising Procaine and Uses Thereof In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned